Multiple Sclerosis Infusion Every 6 Months

Ocrelizumab, sold under the brand name Ocrevus, is the main multiple sclerosis treatment given as an intravenous infusion every six months. Approved by the FDA in 2017, it works by depleting a specific type of immune cell (CD20-positive B cells) that plays a role in MS-related nerve damage. The twice-yearly schedule stands out among MS therapies, most of which require daily pills, frequent self-injections, or monthly infusions. That convenience has made ocrelizumab one of the most widely prescribed MS drugs, but the six-month rhythm also raises practical questions about what happens between infusions, how long each session takes, and what the long-term trade-offs look like.

How B-Cell Depletion Controls MS

The rationale for a twice-yearly infusion traces back to a landmark 2008 trial of rituximab, an older anti-CD20 antibody originally used in cancer treatment. That trial provided some of the first strong evidence that B cells are directly involved in driving relapsing-remitting MS relapses, upending the long-held assumption that T cells were the only immune culprits worth targeting.¹ Ocrelizumab was engineered as a humanized version of the same concept: it binds to CD20 on the surface of B cells, flagging them for destruction by the rest of the immune system. After a single dose, circulating B cells drop to near zero within about two weeks. Because repopulation is slow, a dose roughly every 24 weeks keeps B-cell counts suppressed and, along with them, the inflammatory attacks on myelin that cause relapses and disability progression.

How Well the Six-Month Infusion Works

The efficacy data from the pivotal trials is striking. In two large phase III trials comparing ocrelizumab to interferon beta-1a (a well-established injectable MS drug), the annualized relapse rate was roughly cut in half: 0.16 with ocrelizumab versus 0.29 with interferon, representing about a 46–47% reduction. The effect on MRI-visible brain lesions was even more dramatic, with about a 94–95% reduction in new gadolinium-enhancing lesions compared to the interferon group.² These benefits kicked in fast, too. A separate analysis showed that ocrelizumab reduced new brain lesions within the first four weeks after the initial dose and significantly lowered the relapse rate within the first eight weeks compared to interferon.³

Ocrelizumab also holds a unique position as the only approved therapy for primary progressive MS (PPMS), a form of the disease where disability worsens steadily rather than in relapse-recovery cycles. In the ORATORIO trial, about 33% of people on ocrelizumab experienced confirmed disability progression over 12 weeks, compared with roughly 39% on placebo, a relative reduction of about 24%.⁴ Walking speed also deteriorated less in the treated group, with about a 29% reduction in worsening on a timed walking test.⁵ Those numbers are modest compared to the relapsing-MS results, but for a disease form that previously had zero approved treatments, they were practice-changing.

There is also evidence that how much drug your body is exposed to matters. A dose-exposure analysis found that people in the highest quartile of ocrelizumab exposure had substantially lower rates of disability progression than those in the lowest quartile, both in relapsing MS and in PPMS.⁶ This finding has implications for dosing: people with larger body sizes may clear the drug faster and could theoretically benefit from dose adjustments, though standard dosing remains the norm for now.

What Infusion Day Actually Looks Like

The first dose is split across two infusions given two weeks apart (300 mg each), to reduce the chance of a strong infusion reaction. After that, it’s a single 600 mg infusion every six months. Originally, each session took about 3.5 hours. A randomized trial (ENSEMBLE PLUS) tested whether a shorter, roughly two-hour infusion was equally safe. The rate of infusion-related reactions was virtually identical between the shorter and standard-length groups, with about 27–29% of patients experiencing mild or moderate symptoms like throat irritation or headache. Over 98% of those reactions resolved without lasting problems, and no new safety signals turned up.⁷ A separate study of an even shorter infusion protocol found similar results, with no grade 3 or 4 reactions and no treatment discontinuations due to infusion reactions.⁸

For most people, the practical reality is arriving at an infusion center, getting premedicated with a steroid and antihistamine, sitting through the infusion itself, and then being observed for about an hour afterward. With the shorter protocol, the total visit is closer to three hours rather than five. At the end of ENSEMBLE PLUS, 95% of patients already on the shorter infusion chose to stay with it, and 80% of those who had been on the longer protocol switched to shorter when given the option.⁹

Why People Stay on It

One of the clearest practical advantages of a six-month infusion is that it removes the daily or weekly discipline required by other MS treatments. The adherence numbers reflect this. In a U.S. claims analysis, about 92% of patients starting ocrelizumab remained on therapy through their first year, compared with roughly 72% for other IV drugs, 68% for oral therapies, and 57% for self-injected drugs.¹⁰ By two years, 75% of ocrelizumab patients were still persistent on therapy, versus about 54% for orals and 33% for injectables. People on oral or injectable drugs were two to three times more likely to have stopped treatment by the 24-month mark.¹¹

These persistence gaps matter. MS drugs only work if you take them, and missed doses create windows where disease activity can resume. The six-month schedule eliminates the chance of forgetting a daily pill or skipping a self-injection because the needle stings. You either show up for the infusion or you don’t, and the scheduling machinery of the infusion center helps ensure you do.

The Wearing-Off Problem

Not everyone sails smoothly from one infusion to the next. A phenomenon known as “wearing off” is reported by a significant fraction of people on ocrelizumab. In one survey, about 61% of participants said they experienced some return of MS-like symptoms in the weeks before their next infusion, most commonly fatigue, cognitive fog, and sensory symptoms like numbness or tingling. Of those who reported wearing off, about half said it started one to four weeks before the scheduled infusion, and about a third noticed symptoms more than four weeks ahead of time.¹²

Interestingly, the wearing-off phenomenon did not correlate in that study with B-cell counts, MRI activity, or clinical relapses. The strongest predictor was a higher body mass index (a BMI of 25 or above roughly tripled the odds of experiencing it). A follow-up study, though, found that people who reported wearing off had higher levels of certain T-cell populations and elevated neurofilament light chain, a blood marker of nerve damage. That pattern suggests wearing off may reflect a genuine reduction in the drug’s immunomodulatory effect as the six-month interval draws to a close, not just a subjective perception.¹³

Extended Interval Dosing and Personalized Schedules

The wearing-off issue might suggest people need their infusions more often. But there is a countervailing push in the opposite direction: extending the interval between infusions to reduce long-term side effects, particularly the decline in immunoglobulin levels that comes with sustained B-cell depletion. Under standard dosing, immunoglobulin M (IgM) tends to drop relatively quickly, and IgG can follow over time. In one study, immunoglobulin levels declined significantly over 12 months in people on standard-interval dosing but did not decline in those on extended intervals.¹⁴

A real-world cohort study found that about a third of ocrelizumab-treated patients developed low IgM and about one-sixth developed low IgG, with the strongest predictor being low baseline levels rather than demographics or disease characteristics. Severe infections were uncommon, occurring at a rate of about 1.1 per 100 patient-years, and were not consistently linked to low immunoglobulin levels.¹⁵

The good news is that extending the dosing interval does not appear to let the disease come back. One study showed that stretching the time between ocrelizumab infusions altered B-cell repopulation patterns without increasing the return of inflammatory “effector” B cells, and clinical efficacy was maintained.¹⁶ Researchers have suggested that extending dosing intervals could become a deliberate strategy to minimize B-cell repopulation without compromising MS control.¹⁷ In practice, many neurologists are already doing this, especially for patients who have been stable for years or whose immunoglobulin levels are trending down. The decision is increasingly guided by monitoring B-cell counts and antibody levels rather than sticking rigidly to a calendar.

Vaccine Response and Infection Risk

Because anti-CD20 therapies wipe out the B cells responsible for producing antibodies, they blunt the immune response to vaccines. This became a front-page issue during the COVID-19 pandemic. Research found that whether or not a patient developed antibodies after vaccination was better predicted by the presence of circulating B cells and detectable drug levels in the blood than by time since the last infusion. Patients with B cells making up more than 0.5% of lymphocytes had roughly five times the odds of developing a vaccine antibody response, while patients with detectable rituximab in their blood had dramatically reduced odds of seroconversion.¹⁸

The practical upshot: if you need a vaccine, the timing relative to your infusion cycle matters. Research suggests vaccinating as soon as possible and then delaying the next infusion until B-cell levels have had a chance to recover, at which point a booster dose may help.¹⁹ It is worth emphasizing that even when antibody responses are weak, cellular immune responses (T-cell responses) often remain intact, providing some degree of protection. Still, for vaccines that depend on antibody production, like flu shots and COVID boosters, coordinating the timing with your infusion schedule is something to discuss with your neurologist.

Rituximab as an Off-Label Alternative

Ocrelizumab is not the only anti-CD20 option given as a roughly six-month infusion. Rituximab, the older drug that originally proved the concept, is widely used off-label for MS in many countries, particularly in Scandinavia and in settings where cost is a barrier. A nationwide cost-effectiveness study found that off-label rituximab was associated with lower total healthcare costs (savings ranged from about $35,000 to $66,000 per patient over five years compared to each approved disease-modifying therapy) and slightly fewer relapses, with the price of the drug itself being the main driver of savings.²⁰

Researchers have also explored extended dosing intervals with rituximab. A retrospective analysis found that stretching out rituximab infusions did not lead to worse disability progression. Nearly all patients in the extended-interval group remained relapse-free over a year, and they had significantly fewer serious infections at both six and twelve months compared to people on standard-interval dosing.²¹ The choice between rituximab and ocrelizumab often comes down to insurance coverage and regional practice patterns. Ocrelizumab has the regulatory approval and the phase III trial data behind it; rituximab has years of real-world experience and a dramatically lower price tag.

A Subcutaneous Version on the Horizon

The infusion center visit, even at two hours, is still a barrier for some people. Genentech has developed a subcutaneous formulation of ocrelizumab that can be administered as an injection under the skin in roughly 10 minutes, rather than an hours-long IV drip. The phase III OCARINA II trial showed that the subcutaneous 920 mg dose achieved drug exposure levels that were noninferior to the standard 600 mg IV dose. About 97–98% of patients in both the subcutaneous and IV arms were relapse-free through 48 weeks. Patient satisfaction was high: roughly 96% of those who received the subcutaneous injection said they were satisfied or very satisfied with the procedure.²² This formulation could eventually shift the six-month MS treatment from an infusion center appointment to a quick clinic visit or potentially a home injection, though it would still involve healthcare professional supervision.

Pregnancy Planning Around the Infusion Cycle

Because ocrelizumab is given in discrete doses months apart, the infusion schedule creates natural windows for pregnancy planning. Data from over 2,400 prospectively reported pregnancies showed that live birth rates were similar between women exposed to ocrelizumab in utero and those who were not (about 84% versus 88%). Rates of preterm birth and major congenital abnormalities were also comparable between groups and within general population background rates.²³ In a Canadian cohort, about 64% of women who were not exposed in utero had received their last infusion three to six months before conception, while others had longer washout periods.²⁴

The general approach most neurologists follow is to time the last infusion so that conception occurs several months afterward, allowing some B-cell recovery while the drug clears. This is not a rigid protocol, and the decision depends on how active someone’s MS has been, but the six-month dosing schedule at least makes it possible to plan around a single, known treatment date rather than trying to coordinate with a daily medication.

The Financial Reality

Ocrelizumab’s list price runs in the range of $65,000–$70,000 per year in the United States, though what patients actually pay varies enormously depending on insurance, copay assistance programs, and specialty pharmacy arrangements. Financial burden is not trivial: a study of MS patients found that about a third reported care non-adherence driven by financial toxicity, and roughly two-thirds reported making lifestyle changes because of treatment costs. Greater financial stress correlated with worse quality of life and was more common in people who had recently relapsed.²⁵ This is one of the stronger arguments for rituximab where it is available, though patients should weigh that decision with their neurologists since the two drugs are not identical in their evidence base or regulatory status.

Ofatumumab and Self-Injection Alternatives

For people who want B-cell depletion without the infusion center, ofatumumab (Kesimpta) is a fully human anti-CD20 antibody given as a once-monthly self-injection at home using a prefilled autoinjector. It is not a six-month infusion, but it targets the same pathway. In real-world data, ofatumumab showed higher persistence at 6 and 12 months compared to oral and self-injectable MS therapies, though the comparison with IV drugs like ocrelizumab was not the focus of that particular analysis.²⁶ For some patients, the trade-off between monthly home injections and twice-yearly infusion center visits comes down to personal preference, needle comfort, and whether they value the structure of the infusion center or the flexibility of self-administration.

The landscape of anti-CD20 MS treatment is evolving. Between the standard six-month IV ocrelizumab, extended-interval dosing strategies, the incoming subcutaneous formulation, off-label rituximab at various intervals, and monthly subcutaneous ofatumumab, the underlying therapeutic idea remains the same: keep the problematic B cells suppressed. The differences are in logistics, cost, and how the treatment fits into someone’s life.